Endometriosis Market Expected to Achieve Significant CAGR During the Forecast Period (2026-2036) Driven by Innovative Treatment Options | DelveInsight
The endometriosis market is expected to grow steadily over the forecast period (2026–2036), driven by rising disease awareness, improving diagnosis rates, and advancements in noninvasive diagnostic approaches. Furthermore, the introduction of novel therapeutic options such as HMI-115 (Bayer/Hope Medicine), Merigolix/TU2670 (Tiumbio), Linzagolix (Kissei Pharmaceutical), Vipoglanstat (Gesynta Pharma), Estelle (Mithra Pharmaceuticals), VR103 (VaRi Bioscience), and others is anticipated to address longstanding unmet needs.
LAS VEGAS, March 12, 2026 /PRNewswire/ -- Recently published Endometriosis Market Insights report includes a comprehensive understanding of current treatment practices, endometriosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Endometriosis Market Summary
Discover global endometriosis treatment market size and CAGR @ https://www.delveinsight.com/sample-request/endometriosis-market
Key Factors Driving the Growth of the Endometriosis Market
Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, said that the anticipated launch of novel therapies by key players during the forecast period (2026–2036) is expected to positively influence the endometriosis market in the US, driven by the development of safer, disease-modifying treatments with improved pain management.
Endometriosis Market Analysis
Endometriosis Competitive Landscape
Some of the endometriosis drugs under development include HMI-115 (Bayer/Hope Medicine), Merigolix/TU2670 (Tiumbio), Linzagolix (Kissei Pharmaceutical), Vipoglanstat (Gesynta Pharma), Estelle (Mithra Pharmaceuticals), VR103 (VaRi Bioscience), and others.
Bayer/Hope Medicine's HMI-115 is a novel monoclonal antibody designed to block the prolactin receptor, a central driver of both the formation and maintenance of endometriosis. Prolactin signaling is known to promote lesion growth, inflammation, and pain. By inhibiting this receptor, HMI-115 seeks to reduce endometriosis-related pain and slow lesion development without relying on hormonal suppression.
Tiumbio's TU2670 is an orally administered small-molecule GnRH receptor antagonist that lowers estradiol levels by directly binding to GnRH receptors in the pituitary gland. In contrast to injectable GnRH agonists, which cause deep, menopause-level hormonal suppression and can lead to bone loss and reduced patient comfort, TU2670 allows adjustable, therapeutic-range hormone reduction. This approach aims to maintain effectiveness while minimizing hypoestrogenic side effects and offers greater convenience through oral dosing. A Phase IIa clinical study is currently underway across five European countries to assess TU2670's safety and its ability to relieve endometriosis-associated pain.
Gesynta Pharma is developing vipoglanstat (GS-248), a selective and potent inhibitor of the enzyme mPGES-1. This enzyme plays a crucial role in inflammatory processes and has been specifically linked to endometriosis pathology.
VaRi Bioscience's VR103 vaginal ring provides a continuous release of progestin for three months and is intended to serve as an optimal first-line treatment for endometriosis. Its effectiveness is comparable to that of GnRH agonists and antagonists, but without reducing estrogen levels enough to affect bone mineral density. Its safety and tolerability profile surpasses that of existing progestin-only therapies, with minimal to no estrogen-withdrawal symptoms such as hot flashes, night sweats, vaginal dryness, or mood changes.
The anticipated launch of these emerging therapies are poised to transform the endometriosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the endometriosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about best-selling endometriosis drugs @ Endometriosis Drugs
Recent Developments in the Endometriosis Market
What is Endometriosis?
Endometriosis is a chronic condition in which tissue similar to the lining of the uterus begins to grow outside the uterus, often on the ovaries, fallopian tubes, or other pelvic organs. These abnormal growths respond to hormonal changes during the menstrual cycle, causing inflammation, scarring, and sometimes the formation of cysts. Because this tissue cannot exit the body during menstruation, it can lead to severe pelvic pain, heavy periods, pain during intercourse, and sometimes fertility challenges. Although endometriosis is long-term, its symptoms can be managed through medical treatments, lifestyle adjustments, and, in some cases, surgery.
Endometriosis Epidemiology Segmentation
The endometriosis epidemiology section provides insights into the historical and current endometriosis patient pool and forecasted trends for the leading markets. In the US, diagnosed prevalent cases of endometriosis are predominantly managed by gynecologists, accounting for about 3 million cases in 2025 and generalists represent the second-largest prescriber group, managing roughly 500,000 cases in 2025.
The endometriosis treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Endometriosis Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Endometriosis Epidemiology Segmentation
Prevalent Cases of Endometriosis, Diagnosed Prevalent Cases of Endometriosis, Age-specific Diagnosed Prevalent Cases of Endometriosis, Stage-specific Diagnosed Prevalent Cases of Endometriosis, Prescriber Pattern-specific Diagnosed Prevalent Cases of Endometriosis, and Treated Cases of Endometriosis
Key Endometriosis Companies
Bayer, Hope Medicine, Tiumbio, Kissei Pharmaceutical, Gesynta Pharma, Mithra Pharmaceuticals, VaRi Bioscience, AbbVie, Myovant, Pfizer, and others
Key Endometriosis Therapies
HMI-115, Merigolix/TU2670, Linzagolix, Vipoglanstat, Estelle, VR103, ORILISSA, MYFEMBREE/RYEQO, and others
Scope of the Endometriosis Market Report
Download the report to understand top endometriosis therapies and market trends @ Endometriosis Market Analysis
Table of Contents
1
Endometriosis Market Key Insights
2
Endometriosis Market Report Introduction
3
Endometriosis Market Overview
3.1
Market Share (%) Distribution of Endometriosis by Therapies in the US in 2025
3.2
Market Share (%) Distribution of Endometriosis by Therapies in the US in 2036
4
Methodology of Epidemiology and Market
5
Executive Summary
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Causes
7.3
Pathophysiology
7.4
Symptoms
7.5
Diagnosis
7.6
Treatment and Management of Endometriosis
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale: The US
8.2.1
Prevalent Cases of Endometriosis
8.2.2
Diagnosed Prevalent Cases of Endometriosis
8.2.3
Age-specific Diagnosed Prevalent Cases of Endometriosis
8.2.4
Stage-specific Diagnosed Prevalent Cases of Endometriosis
8.2.5
Prescriber Pattern-specific Diagnosed Prevalent Cases of Endometriosis
8.4
The US
8.4.1
Prevalent Cases of Endometriosis
8.4.2
Diagnosed Prevalent Cases of Endometriosis
8.4.3
Age-specific Diagnosed Prevalent Cases of Endometriosis
8.4.4
Stage-specific Diagnosed Prevalent Cases of Endometriosis
8.4.5
Prescriber Pattern-specific Diagnosed Prevalent Cases of Endometriosis
8.4.6
Total Treated Cases of Endometriosis
8.5
EU4 and the UK
8.6
Japan
9
Endometriosis Patient Journey
10
Marketed Endometriosis Therapies
10.1
Key Cross Competition
10.2
ORILISSA (elagolix): AbbVie
10.2.1
Product Description
10.2.2
Regulatory Milestone
10.2.3
Other Developmental Activities
10.2.4
Clinical Trials Information
10.2.5
Safety and Efficacy
10.3
MYFEMBREE/RYEQO (relugolix, estradiol, and norethindrone acetate): Myovant/Pfizer
List to be continued in the report…
11
Emerging Endometriosis Therapies
11.1
Key Cross Competition
11.2
HMI-115: Bayer/Hope Medicine
11.2.1
Drug Description
11.2.2
Other Developmental Activities
11.2.3
Clinical Trials Information
11.2.4
Safety and Efficacy
11.2.5
Analyst Views
11.3
Merigolix/TU2670: Tiumbio/ Hansoh Pharma
List to be continued in the report…
12
Endometriosis: Market Analysis
12.1
Key Findings
12.2
Key Endometriosis Market Forecast Assumptions
12.3
Attribute Analysis
12.4
US Endometriosis Market Outlook
12.5
Total Market Size of Endometriosis in the US
12.6
Market Size of Endometriosis by Therapies in the US
12.7
EU4 and the UK Endometriosis Market Outlook
12.8
Japan Endometriosis Market Outlook
13
Key Opinion Leaders' Views on Endometriosis
14
Endometriosis Market SWOT Analysis
15
Endometriosis Market Unmet needs
16
Endometriosis Market Access and Reimbursement
17
Bibliography
18
Acronyms and Abbreviations
19
Endometriosis Market Report Methodology
Related Reports
Endometriosis Clinical Trial Analysis
Endometriosis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Hope Medicine Inc, Gesynta Pharma AB, Changchun GeneScience Pharmaceutical Co., Ltd., TiumBio, Jiangsu Hengrui Medicine Co, EpicentRx, NETRIS Pharma, Maipl Therapeutics, Temple Therapeutics, Cartherics Pty Ltd, among others.
Endometriosis Pain Market
Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies including Horizon Therapeutics (Amgen), Dompe Farmaceutici, Sylentis, MorphoSys, Resolve Therapeutics, OSE Immunotherapeutics, Servier, Novartis, Johnson & Johnson, among others.
Endometriosis Pain Clinical Trial Analysis
Endometriosis Pain Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, TiumBio Co., Ltd., Mitsubishi Tanabe Pharma, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP